HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

HspX-mediated protection against tuberculosis depends on its chaperoning of a mycobacterial molecule.

Abstract
New approaches consisting of 'multistage' vaccines against (TB) are emerging that combine early antigenic proteins with latency-associated antigens. In this study, HspX was tested for its potential to elicit both short- and long-term protective immune responses. HspX is a logical component in vaccine strategies targeting protective immune responses against primary infection, as well as against reactivation of latent infection, because as previously shown, it is produced during latency, and as our studies show, it elicits protection within 30 days of infection. Recent studies have shown that the current TB vaccine, bacilli Calmette-Guerin (BCG), does not induce strong interferon-γ T-cell responses to latency-associated antigens like HspX, which may be in part why BCG fails to protect against reactivation disease. We therefore tested HspX protein alone as a prophylactic vaccine and as a boost to BCG vaccination, and found that HspX purified from M. tuberculosis cell lysates protected mice against aerosol challenge and improved the protective efficacy of BCG when used as a booster vaccine. Native HspX was highly immunogenic and protective, in a dose-dependent manner, in both short- and long-term infection models. Based on these promising findings, HspX was produced as a recombinant protein in E. coli, as this would enable facile purification; however, recombinant HspX (rHspX) alone consistently failed to protect against aerosol challenge. Incubation of rHspX with mycobacterial cell lysate and re-purification following incubation restored the capacity of the protein to confer protection. These data suggest the possibility that the native form may chaperone an immunogenic and protective antigen that is mycobacteria-specific.
AuthorsJennifer L Taylor, Agatha Wieczorek, Andrew R Keyser, Ajay Grover, Rachel Flinkstrom, Russell K Karls, Helle Bielefeldt-Ohmann, Karen M Dobos, Angelo A Izzo
JournalImmunology and cell biology (Immunol Cell Biol) Vol. 90 Issue 10 Pg. 945-54 (Nov 2012) ISSN: 1440-1711 [Electronic] United States
PMID22801575 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Bacterial
  • Bacterial Proteins
  • HspX protein, Mycobacterium tuberculosis
  • Molecular Chaperones
  • Tuberculosis Vaccines
  • Interferon-gamma
Topics
  • Animals
  • Antigens, Bacterial (genetics, immunology, metabolism)
  • Bacterial Proteins (genetics, immunology, metabolism)
  • Cells, Cultured
  • Escherichia coli (genetics)
  • Female
  • Humans
  • Immunity, Active (genetics)
  • Interferon-gamma (metabolism)
  • Mice
  • Mice, Inbred C57BL
  • Molecular Chaperones (genetics, immunology, metabolism)
  • Transgenes (genetics)
  • Tuberculosis (prevention & control)
  • Tuberculosis Vaccines (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: